BioCentury & Getty Images

Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

Jan 16, 2021 | 2:21 AM GMT

Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract

Read the full 435 word article

How to gain access

Continue reading with a
two-week free trial.